With the antibody market projected to reach a staggering $300 billion by 2025, attention is now shifting to refining the often-arduous and time-consuming processes of antibody discovery. Particularly challenging are targets like G protein-coupled receptors (GPCRs), which play vital roles in cellular signaling but present formidable obstacles due to variable conformation, limited immunogenicity, and their elusive nature.
Amid these challenges, a groundbreaking solution emerges—the Opto® Plasma B Discovery Workflow. This revolutionary approach not only slashes the time required for lead molecule selection to a mere week but also enhances the quality of hits, even with notorious targets.
As we stand on the precipice of a new era in medical research, this revolutionary workflow beckons researchers to transcend the limitations of traditional methods, offering a streamlined path to discovering antibodies that could reshape the landscape of therapeutic interventions. The future of antibody discovery is now, and it is illuminated by the Opto® Plasma B Discovery Workflow—a testament to the relentless pursuit of excellence in the quest for transformative medical solutions.
Download this eBook to learn more about:
- The challenges of antibody discovery
- The difficulties of GPCR discovery
- How Bruker’s novel antibody discovery workflow improves the accuracy and efficiency of antibody discovery
- How you can implement Bruker’s improved workflows in your antibody research
